公开(公告)号：US20220002278A9

公开(公告)日：2022-01-06

申请号：US17075206

申请日：2020-10-20

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU INSTITUTE OF DRUG INNOVATION, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Bing Zhou ,  Cheng Luo ,  Hualiang Jiang ,  Yaxi Yang ,  Lianghe Mei ,  Wenchao Lu ,  Senhao Xiao ,  Shijie Chen ,  Shili Wan ,  Gang Qiao ,  Rukang Zhang

IPC: C07D413/06 ,  C07D417/06 ,  C07D413/14 ,  C07D491/107 ,  C07D513/04 ,  C07D471/04 ,  C07D495/04 ,  C07D495/10

Abstract: Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

公开(公告)号：US20250154121A1

公开(公告)日：2025-05-15

申请号：US18833602

申请日：2023-01-19

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES

Inventor： Chenggang HUANG ,  Xiaolan CUI ,  Yang XIE ,  Xiaoting TIAN ,  Shanshan GUO ,  Zhixiong LI ,  Yingjie GAO

IPC: C07D311/36 ,  A61K31/352 ,  A61P31/14 ,  A61P31/16

Abstract: A novel compound represented by general formula I, a pharmaceutically acceptable salt thereof, a solvate, a stereoisomer including mixtures thereof in all ratios, and a pharmaceutical composition containing the compound are provided. Also provided are preparation method for the compound, and applications of the compound, the pharmaceutically acceptable salt thereof, the solvate, and the stereoisomer including the mixtures in all ratios, and in particular to a use of the compound in the preparation of antiviral drugs.

公开(公告)号：US20250122148A1

公开(公告)日：2025-04-17

申请号：US18728641

申请日：2023-01-10

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Zhaobing GAO ,  Wuheng DONG ,  Yueming ZHENG ,  Jintao WANG ,  Xiaoyu ZHOU ,  Huanan LIU ,  Haiyan XU

IPC: C07C269/04 ,  A61K31/27 ,  A61P21/00

Abstract: Disclosed are a high-selectivity KCNQ4 potassium channel agonist of formula I, a preparation method therefor and the use thereof. The compound further improves the KCNQ4 agonistic activity, and is still free of KCNQ2 agonistic activity, thus having excellent KCNQ4/KCNQ2 selectivity. The high-selectivity KCNQ4 agonist overcomes the defect of poor selectivity of existing potassium channel agonists, the activity is relatively increased, and the toxicity is remarkably reduced. The agonist also has a simpler structure and lower product cost, thereby having a better development prospect.

公开(公告)号：US20250090547A1

公开(公告)日：2025-03-20

申请号：US18724128

申请日：2023-02-28

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Yong GAN ,  Xinxin ZHANG ,  Linmiao GUO ,  Yunqiu MIAO ,  Xiaoli WANG ,  Ying ZHANG ,  Chunliu ZHU

IPC: A61K31/557 ,  A61K9/00 ,  A61K9/107 ,  A61K47/24

Abstract: The present application relates to an EPA-EE nano-lipid composition and a formulation, a preparation method, and an application thereof. The EPA-EE nano-lipid composition includes a raw material having a high content of EPA-EE as a primary ingredient and includes an emulsifier containing a highly unsaturated phospholipid. The EPA-EE nano-lipid composition can be prepared into a sub-micron emulsion at nanoscale for use as an oral formulation.

公开(公告)号：US12240841B2

公开(公告)日：2025-03-04

申请号：US17603823

申请日：2020-04-20

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences ,  Van Andel Research Institute

Inventor： Huaqiang Xu ,  Jia Li ,  Jingjing Shi ,  Yi Zang ,  Dandan Sun ,  Mingliang Liu ,  Rongrong Xie ,  Erli You ,  Lixin Gao ,  Qian Tan

IPC: C07D413/14 ,  A61P1/16 ,  C07D487/08

Abstract: An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases.

公开(公告)号：US20250059219A1

公开(公告)日：2025-02-20

申请号：US18556165

申请日：2022-03-25

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU QINGYA QIRUI BIOTECHNOLOGY CO., LTD.

Inventor： Jianhua SHEN ,  Zhiyuan ZHU ,  Xiaomei LI ,  Kai WANG ,  Jia LIU

IPC: C07F9/655 ,  A61K31/365 ,  A61K31/665 ,  A61P1/00 ,  A61P1/16 ,  A61P11/00 ,  A61P19/02 ,  A61P25/28 ,  A61P35/00 ,  A61P35/02 ,  C07D307/33

Abstract: Disclosed in the present invention are a lignan derivative, a preparation method therefor and the use thereof. The structure of the lignan derivative is as shown in a formula I, wherein in the formula, the definition of each substituent is as described in the description and claims. The lignan derivative of the present invention can be used as an inhibitor of mitochondrial respiratory chain complex I to inhibit mitochondrial oxidative phosphorylation and ATP generation, and can also be used for preventing and/or treating diseases associated with the elevated activity or expression of the mitochondrial respiratory chain complex I or enhanced mitochondrial oxidative phosphorylation.

公开(公告)号：US20240150300A1

公开(公告)日：2024-05-09

申请号：US18278063

申请日：2022-02-18

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Youhong HU ,  Meiyu GENG ,  Daqiang LI ,  Aijun SHEN ,  Zhuo ZHANG ,  Yalei LI ,  Huajie YANG ,  Hongchun LIU ,  Hanyue ZHONG ,  Jian DING

IPC: C07D237/14 ,  A61P35/00 ,  A61P35/02 ,  C07C67/00 ,  C07C67/10 ,  C07D401/04 ,  C07D403/04

CPC classification number: C07D237/14 ,  A61P35/00 ,  A61P35/02 ,  C07C67/00 ,  C07C67/10 ,  C07D401/04 ,  C07D403/04

Abstract: The present invention relates to an S-configuration-containing amino benzamide pyridazinone compound, a preparation method therefor, and a pharmaceutical composition and application thereof. Specifically, the present invention relates to a compound represented by the following general formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and application thereof. The S-configuration compound of the present application has very strong binding activity on class I histone deacetylase (HDAC1), and shows inhibitory activity on in-vitro proliferation of various tumor cells.

公开(公告)号：US20240059676A1

公开(公告)日：2024-02-22

申请号：US18267298

申请日：2021-12-10

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Bing Zhou ,  Ying Leng ,  Yaxi Yang ,  Mengmeng Ning ,  Liuyu Hu ,  Lei Feng ,  Ju Liang

IPC: C07D403/10 ,  C07D413/10 ,  C07D471/04 ,  A61P3/06

CPC classification number: C07D403/10 ,  C07D413/10 ,  C07D471/04 ,  A61P3/06

Abstract: The present invention relates to a thyroid hormone receptor β selective agonist compound represented by formula I, a pharmaceutical composition and use thereof. The compound improves the selectivity to THR-α and the druggability of the compound while maintaining good THR-β agonistic activity, and shows a certain activity in in vivo pharmacological experiments.

公开(公告)号：US11873292B2

公开(公告)日：2024-01-16

申请号：US16306751

申请日：2017-06-02

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Hong Liu ,  Jia Li ,  Wei Zhu ,  Yubo Zhou ,  Jiang Wang ,  Mingbo Su ,  Shuni Wang ,  Wei Xu ,  Chunpu Li ,  Weijuan Kan ,  Hualiang Jiang ,  Kaixian Chen

IPC: C07D403/12 ,  C07D215/58 ,  C07D209/04 ,  C07D215/00 ,  C07D487/04 ,  C07D209/08 ,  C07D401/12 ,  C07D405/12 ,  A61P35/00

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D209/04 ,  C07D209/08 ,  C07D215/00 ,  C07D215/58 ,  C07D401/12 ,  C07D405/12 ,  C07D487/04 ,  Y02P20/55

Abstract: The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.

公开(公告)号：US20230219993A1

公开(公告)日：2023-07-13

申请号：US17996430

申请日：2021-04-16

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCE ,  XINJIANG TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY, CHINESE ACADEMIY OF SCIENCES ,  VIGONVITA LIFE SCIENCES CO., LTD.

Inventor： Yuanchao XIE ,  Gengfu XIAO ,  Yang HE ,  Leike ZHANG ,  Heji Akber AISA ,  Hualiang JIANG ,  Jingshan SHEN

IPC: C07H7/06 ,  A61P31/14 ,  A61P31/16

CPC classification number: C07H7/06 ,  A61P31/14 ,  A61P31/16 ,  C07B2200/05

Abstract: The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia
(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.